BioOrbit completes orbital protein crystallisation experiment

BioOrbit completes orbital protein crystallisation experiment

BioOrbit has completed its first pharmaceutical manufacturing experiment in orbit. The six-week International Space Station test produced protein crystals, but no drug formulated using the process has yet demonstrated clinical safety or efficacy.


BioOrbit has completed an International Space Station experiment that produced protein crystals under microgravity conditions, testing an early manufacturing step for concentrated pharmaceutical formulations. The British biotechnology company operated its Baby BOX-E platform for approximately six weeks in orbit, with results intended to inform further development on Earth.

The mission launched in May aboard a SpaceX flight from NASA's Kennedy Space Center. UK Research and Innovation confirmed the completed work on 23 October, alongside a £9.8 million seed funding round announced by BioOrbit. The investment is financing the company's wider development ambitions; it should not be described as the cost of the single flight or as a commercial order for manufactured medicines.

BioOrbit is examining whether therapeutic proteins crystallised in microgravity could form the basis of concentrated medicines delivered in smaller volumes. Certain antibody-based cancer treatments are currently administered by intravenous infusion; the company's longer-term objective is to explore formulations that might instead be suitable for injection outside an infusion clinic. No such product has yet been approved from this programme.

Crystallisation is a controlled manufacturing process in which molecules arrange themselves into repeating ordered structures. The outcome depends on the material, solution chemistry, temperature, concentration and the movement of fluid around growing crystals. Different growth conditions can produce particles with different dimensions, degrees of uniformity and structural quality, which in turn influence subsequent handling and formulation.

On Earth, density differences within a liquid can produce convection currents, while growing crystals may settle under gravity. These effects can alter the local supply of dissolved material and disturb the conditions at a developing crystal surface. A microgravity environment reduces some of those gravity-driven effects, allowing scientists to examine crystal growth under different transport conditions.

Research described by NASA and the International Space Station National Laboratory shows that particular proteins can form larger or more consistently ordered crystals in microgravity. The outcome is dependent on the protein and the experimental conditions; spaceflight does not automatically improve every formulation or guarantee a higher manufacturing yield.

Baby BOX-E was designed to test crystal production as a manufacturing operation rather than solely to generate material for structural analysis. UKRI describes it as the largest-scale production of protein crystals in space to date, although its public account does not provide comparable batch mass or yield figures to substantiate that ranking independently. The publicly reported result establishes an experiment, not commercially repeatable output.

A crystal grown for scientific analysis is not automatically a pharmaceutical ingredient ready for use. Repeated commercial batches would need specifications for identity, purity, consistency and stability, as well as controlled processing and release testing. Any change to crystal structure or formulation must also be assessed for its effect on the medicine's performance and safety.

Producing crystals in orbit presents its own operating constraints. Hardware must withstand launch conditions, fit within a limited payload volume and maintain appropriate processing parameters while access for maintenance or intervention is restricted. The materials must then survive return and subsequent processing on Earth without losing the characteristics that made the orbital stage potentially useful.

UKRI reports that Baby BOX-E remained in orbit for around six weeks, during which compounds crystallised into relatively uniform structures. It has not published a full technical dossier setting out the identity of every compound, the mass produced, measured distribution of crystal sizes or a comparative yield from an equivalent terrestrial process.

The next engineering steps include characterising the crystals, establishing whether the properties are reproducible and demonstrating that they can be formulated into a stable product. Even if orbital crystal growth is favourable, a production process would need controlled downstream handling and reliable dosing through the chosen delivery device. UKRI has not published a full comparative technical dossier or commercial manufacturing yield.

The proposed clinical application involves biologic medicines, including antibody-based treatments used in oncology. Such treatments can require large quantities of active molecules per dose, making concentration and viscosity important formulation properties. A more concentrated product may reduce the amount of liquid administered, but the formulation must remain suitable for injection, and the treatment's clinical performance cannot be inferred simply from its crystal structure.

BioOrbit's proposed treatment model depends on drug-specific evidence, including what happens when the material is dissolved or suspended, how it is administered and whether the final formulation delivers the intended dose safely. The successful orbital test provides no patient outcomes, and improvements in crystal uniformity alone cannot demonstrate that a medicine can replace an intravenous infusion.

Any projected saving from shifting administration out of hospital is conditional on successful drug development and a practical supply chain. Orbital processing adds launch, payload, return, quality control and regulatory requirements to conventional pharmaceutical manufacturing. These costs would need to be weighed against changes in clinical administration before an overall economic benefit could be established.

BioOrbit was founded by scientist Dr Katie King and oncology researcher Dr Leonor Teles and has been part of the European Space Agency Business Incubation Centre UK since 2023. A separate £250,000 UK Space Agency feasibility study announced earlier in 2026 concerns the regulatory and technical pathway for drug production in orbit, with input from UK medicines and aviation authorities.

The newly announced £9.8 million seed round supports the company's development programme beyond one ISS experiment. UKRI describes the sum as a record seed investment for an in-space pharmaceutical manufacturing start-up. Neither the financing nor the successful crystallisation establishes a batch cost, full-scale manufacturing capability or clinical effectiveness.

BioOrbit has previously stated an ambition to establish a pharmaceutical manufacturing facility in space within a decade. Meeting that ambition would require equipment able to deliver repeated output under controlled conditions, a viable route for samples or finished material to reach Earth, and validated procedures accepted by medicines regulators.

The mission has established that BioOrbit's platform could conduct a six-week orbital crystallisation experiment. Detailed composition, recovered quantities, comparison with ground-grown material and reproducibility across further missions remain unavailable in the public results. Those measurements will govern how much of the experimental process can be carried into pharmaceutical development.


Stories for you